FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:2186-2195 May 29, 2003 Number 22 Next

	Full Text PDF PDA Full Text Perspective by Steinbrook, R. Editorial by Tashima, K. T. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The T-20 vs. Optimized Regimen Only Study 2 (TORO 2) compared the efficacy and safety of 24 weeks of treatment with the fusion inhibitor enfuvirtide in combination with an optimized background antiretroviral regimen with the efficacy and safety of the optimized background regimen alone.

Methods The patients had previous treatment with each of the three classes of antiretroviral drugs, documented resistance to each class, or both and a plasma level of human immunodeficiency virus type 1 (HIV-1) RNA of at least 5000 copies per milliliter. They were randomly assigned in a 2:1 ratio to receive either enfuvirtide (90 mg twice daily) plus a background regimen optimized with the aid of resistance testing (enfuvirtide group) or the background regimen alone (control group).

Results Of the 512 patients who underwent randomization, 335 in the enfuvirtide group and 169 in the control group received at least one dose of study medication and had at least one follow-up measurement of plasma HIV-1 RNA. The median base-line plasma HIV-1 RNA level was 5.1 log₁₀ copies per milliliter in both groups. The median CD4+ cell count was 98.0 cells per cubic millimeter in the enfuvirtide group and 101.5 cells per cubic millimeter in the control group. Patients had a median of seven years of previous treatment and had received a median of 12 antiretroviral drugs. The background regimen comprised a mean of four antiretroviral drugs in both groups. At 24 weeks, the least-squares mean change from base line in the plasma viral load (intention-to-treat, last observation carried forward) was a decrease of 1.429 log₁₀ copies per milliliter in the enfuvirtide group and a decrease of 0.648 log₁₀ copies per milliliter in the control group, a difference of 0.781 log₁₀ copies per milliliter (P<0.001). The mean increase in the CD4+ cell count was greater in the enfuvirtide group (65.5 cells per cubic millimeter) than in the control group (38.0 cells per cubic millimeter, P=0.02).

Conclusions The addition of enfuvirtide to an optimized background regimen provided significant viral suppression and immunologic benefit over a 24-week period in HIV-1–infected patients who had previously received multiple antiretroviral drugs.

Source Information

From the Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Vita-Salute University, Milan, Italy (A.L.); the Hospital Universitari Germans Trias i Pujol and the Institut de Recerca de la SIDA–Caixa Foundation, Badalona, Barcelona, Spain (B.C.); the National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia (D.C.); the University Hospital of Montpellier, Montpellier, France (J.R.); EPIMED, Vivantes Auguste-Viktoria Hospital, Berlin, Germany (K.A.); the Chelsea and Westminster Hospital, London (M.N.); the Hôpital Pitié-Salpêtrière, Paris (C.K.); the University Hospital Eppendorf, Hamburg, Germany (H.-J.S.); the Centre Hospitalier Universitaire Bicêtre, Assistance Publique–Hôpitaux de Paris, Paris (J.-F.D.); the Academic Medical Center, University of Amsterdam, Amsterdam (J.L.); Roche Products, Welwyn, Hertfordshire, United Kingdom (L.H., C.W.); Trimeris, Durham, N.C. (R.D., J.D., C.D.); and Roche, Nutley, N.J. (M.S.).

Address reprint requests to Dr. Lazzarin at the Clinic of Infectious Diseases, IRCCS, San Raffaele Vita-Salute University, Via Stamira d'Ancona 20, 20127 Milan, Italy, or at lazzarin.adriano{at}hsr.it.

Full Text of this Article

Related Letters:

Enfuvirtide, an HIV-1 Fusion Inhibitor
Carr A., Jenny-Avital E. R., Lalezari J. P., Lazzarin A., Salgo M.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:1770-1771, Oct 30, 2003. Correspondence

This article has been cited by other articles:

• Fulco, P. P., Hynicka, L., Rackley, D. (2010). Raltegravir-Based HAART Regimen in a Patient with Large B-Cell Lymphoma. The Annals of Pharmacotherapy 44: 377-382 [Abstract] [Full Text]  
• Huet, T., Kerbarh, O., Schols, D., Clayette, P., Gauchet, C., Dubreucq, G., Vincent, L., Bompais, H., Mazinghien, R., Querolle, O., Salvador, A., Lemoine, J., Lucidi, B., Balzarini, J., Petitou, M. (2010). Long-Lasting Enfuvirtide Carrier Pentasaccharide Conjugates with Potent Anti-Human Immunodeficiency Virus Type 1 Activity. Antimicrob. Agents Chemother. 54: 134-142 [Abstract] [Full Text]  
• Kousignian, I., Launay, O., Mayaud, C., Rabaud, C., Costagliola, D., Abgrall, S., on behalf of the FHDH-ANRS CO4, (2010). Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?. J Antimicrob Chemother 65: 138-144 [Abstract] [Full Text]  
• Morilla, M. E., Kocher, J., Harmaty, M. (2009). Localized Amyloidosis at the Site of Enfuvirtide Injection. ANN INTERN MED 151: 515-516 [Full Text]  
• Markosyan, R. M., Leung, M. Y., Cohen, F. S. (2009). The Six-Helix Bundle of Human Immunodeficiency Virus Env Controls Pore Formation and Enlargement and Is Initiated at Residues Proximal to the Hairpin Turn. J. Virol. 83: 10048-10057 [Abstract] [Full Text]  
• Kliger, Y., Levy, O., Oren, A., Ashkenazy, H., Tiran, Z., Novik, A., Rosenberg, A., Amir, A., Wool, A., Toporik, A., Schreiber, E., Eshel, D., Levine, Z., Cohen, Y., Nold-Petry, C., Dinarello, C. A., Borukhov, I. (2009). Peptides modulating conformational changes in secreted chaperones: From in silico design to preclinical proof of concept. Proc. Natl. Acad. Sci. USA 106: 13797-13801 [Abstract] [Full Text]  
• O'Rourke, S. M., Schweighardt, B., Scott, W. G., Wrin, T., Fonseca, D. P. A. J., Sinangil, F., Berman, P. W. (2009). Novel Ring Structure in the gp41 Trimer of Human Immunodeficiency Virus Type 1 That Modulates Sensitivity and Resistance to Broadly Neutralizing Antibodies. J. Virol. 83: 7728-7738 [Abstract] [Full Text]  
• Sayana, S., Prosser, P., Ricaurte, J. C., Sanchez, S., Hamwi, G., Hershey-Weber, J., Chien, C., Easley, A., Nguyen, T., Wilson, L., Khanlou, H. (2009). Analysis of a Switch From Enfuvirtide to Raltegravir in Patients With Undetectable Viral Load: Efficacy and Quality of Life at 24 Weeks. J Int Assoc Physicians AIDS Care (Chic Ill) 8: 85-86  
• Naito, T., Izumi, K., Kodama, E., Sakagami, Y., Kajiwara, K., Nishikawa, H., Watanabe, K., Sarafianos, S. G., Oishi, S., Fujii, N., Matsuoka, M. (2009). SC29EK, a Peptide Fusion Inhibitor with Enhanced {alpha}-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide. Antimicrob. Agents Chemother. 53: 1013-1018 [Abstract] [Full Text]  
• Izumi, K., Kodama, E., Shimura, K., Sakagami, Y., Watanabe, K., Ito, S., Watabe, T., Terakawa, Y., Nishikawa, H., Sarafianos, S. G., Kitaura, K., Oishi, S., Fujii, N., Matsuoka, M. (2009). Design of Peptide-based Inhibitors for Human Immunodeficiency Virus Type 1 Strains Resistant to T-20. J. Biol. Chem. 284: 4914-4920 [Abstract] [Full Text]  
• Champagne, K., Shishido, A., Root, M. J. (2009). Interactions of HIV-1 Inhibitory Peptide T20 with the gp41 N-HR Coiled Coil. J. Biol. Chem. 284: 3619-3627 [Abstract] [Full Text]  
• Jacobson, J. M., Kuritzkes, D. R., Godofsky, E., DeJesus, E., Larson, J. A., Weinheimer, S. P., Lewis, S. T. (2009). Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults. Antimicrob. Agents Chemother. 53: 450-457 [Abstract] [Full Text]  
• Clotet, B., Capetti, A., Soto-Ramirez, L. E., Gatell, J. M., Rowell, L., Salgo, M., Schapiro, J. M. (2008). A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study. J Antimicrob Chemother 62: 1374-1378 [Abstract] [Full Text]  
• Borras-Blasco, J., Navarro-Ruiz, A., Borras, C., Castera, E. (2008). Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother 62: 879-888 [Abstract] [Full Text]  
• Belperio, P. S, Mole, L. A, Halloran, J., Boothroyd, D. B, Thomas, I-C., Backus, L. I (2008). Postmarketing Use of Enfuvirtide in Veterans: Provider Compliance with Criteria for Use, Overall Efficacy, and Tolerability. The Annals of Pharmacotherapy 42: 1573-1580 [Abstract] [Full Text]  
• Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A., Wohlfeiler, M., Montana, J. B., McHale, M., Sullivan, J., Ridgway, C., Felstead, S., Dunne, M. W., van der Ryst, E., Mayer, H., the MOTIVATE Study Teams, (2008). Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. NEJM 359: 1429-1441 [Abstract] [Full Text]  
• Fatkenheuer, G., Nelson, M., Lazzarin, A., Konourina, I., Hoepelman, A. I.M., Lampiris, H., Hirschel, B., Tebas, P., Raffi, F., Trottier, B., Bellos, N., Saag, M., Cooper, D. A., Westby, M., Tawadrous, M., Sullivan, J. F., Ridgway, C., Dunne, M. W., Felstead, S., Mayer, H., van der Ryst, E., the MOTIVATE 1 and MOTIVATE 2 Study Teams, (2008). Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection. NEJM 359: 1442-1455 [Abstract] [Full Text]  
• Demarest, J. F., Sparks, S. S., Schell, K., Shibayama, S., McDanal, C. B., Fang, L., Adkison, K. K., Shachoy-Clark, A., Piscitelli, S. C. (2008). In Vitro and Clinical Investigation of the Relationship Between CCR5 Receptor Occupancy and Anti-HIV Activity of Aplaviroc. J Clin Pharmacol 48: 1179-1188 [Abstract] [Full Text]  
• Madeddu, G., Calia, G. M., Campus, M. L., Lovigu, C., Mannazzu, M., Olmeo, P., Mela, M. G., Mura, M. S. (2008). Successful prevention of multidrug resistant HIV mother-to-child transmission with enfuvirtide use in late pregnancy. Int J STD AIDS 19: 644-645 [Abstract] [Full Text]  
• Denoeud, L., Pacanowski, J., Welker, Y., Moulignier, A., Girard, P.-M. (2008). Staphylococcus aureus Brain Abscess in an HIV-Infected Patient Exposed to Enfuvirtide. J Int Assoc Physicians AIDS Care (Chic Ill) 7: 217-219 [Abstract]  
• de Requena, D. G., Bonora, S., Castagna, A., Hasson, H., Marucco, D. A., D'Avolio, A., Sciandra, M., Trentini, L., Calcagno, A., Lazzarin, A., Di Perri, G. (2008). Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. J Antimicrob Chemother 62: 384-387 [Abstract] [Full Text]  
• Baldwin, C., Berkhout, B. (2008). Mechanistic Studies of a T20-Dependent Human Immunodeficiency Virus Type 1 Variant. J. Virol. 82: 7735-7740 [Abstract] [Full Text]  
• Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Zhao, J., Chen, J., Ryan, D. M., Rhodes, R. R., Killar, J. A., Gilde, L. R., Strohmaier, K. M., Meibohm, A. R., Miller, M. D., Hazuda, D. J., Nessly, M. L., DiNubile, M. J., Isaacs, R. D., Nguyen, B.-Y., Teppler, H., the BENCHMRK Study Teams, (2008). Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. NEJM 359: 339-354 [Abstract] [Full Text]  
• Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Zhao, J., Chen, J., Ryan, D. M., Rhodes, R. R., Killar, J. A., Gilde, L. R., Strohmaier, K. M., Meibohm, A. R., Miller, M. D., Hazuda, D. J., Nessly, M. L., DiNubile, M. J., Isaacs, R. D., Teppler, H., Nguyen, B.-Y., the BENCHMRK Study Teams, (2008). Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. NEJM 359: 355-365 [Abstract] [Full Text]  
• Battegay, M., Fehr, J., Fluckiger, U., Elzi, L. (2008). Antiretroviral therapy of late presenters with advanced HIV disease. J Antimicrob Chemother 62: 41-44 [Abstract] [Full Text]  
• Allavena, C., Prazuck, T., Reliquet, V., Verdon, R., Perre, P., Le Moal, G., Billaud, E., Raffi, F. (2008). Impact of Education and Support on the Tolerability and Quality of Life in a Cohort of HIV-1 Infected Patients Treated With Enfuvirtide (SURCOUF Study). J Int Assoc Physicians AIDS Care (Chic Ill) 7: 187-192 [Abstract]  
• Eggink, D., Baldwin, C. E., Deng, Y., Langedijk, J. P. M., Lu, M., Sanders, R. W., Berkhout, B. (2008). Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 Variants. J. Virol. 82: 6678-6688 [Abstract] [Full Text]  
• Saberi, P., Caswell, N. H, Gruta, C. I, Tokumoto, J. N, Dong, B. J (2008). Immunologic Benefits of Enfuvirtide in Patients Enrolled in a Drug Assistance Program. The Annals of Pharmacotherapy 42: 621-626 [Abstract] [Full Text]  
• Kajiwara, K., Kodama, E., Sakagami, Y., Naito, T., Matsuoka, M. (2008). Dual-Reporter Phenotypic Assay for Human Immunodeficiency Viruses. J. Clin. Microbiol. 46: 792-795 [Abstract] [Full Text]  
• Llibre, J. M., Domingo, P., del Pozo, M. A., Miralles, C., Galindo, M. J., Viciana, I., Moreno, S., Schapiro, J. M., Clotet, B. (2008). Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients. J Antimicrob Chemother 61: 206-209 [Abstract] [Full Text]  
• Heredia, A., Gilliam, B., Latinovic, O., Le, N., Bamba, D., DeVico, A., Melikyan, G. B., Gallo, R. C., Redfield, R. R. (2007). Rapamycin Reduces CCR5 Density Levels on CD4 T Cells, and This Effect Results in Potentiation of Enfuvirtide (T-20) against R5 Strains of Human Immunodeficiency Virus Type 1 In Vitro. Antimicrob. Agents Chemother. 51: 2489-2496 [Abstract] [Full Text]  
• Ray, N., Harrison, J. E., Blackburn, L. A., Martin, J. N., Deeks, S. G., Doms, R. W. (2007). Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors. J. Virol. 81: 3240-3250 [Abstract] [Full Text]  
• Zhang, X., Lin, T., Bertasso, A., Evans, C., Dorr, A., Kolis, S. J., Salgo, M., Patel, I., on behalf of the T20-310/NV16056 Study Group, (2007). Population Pharmacokinetics of Enfuvirtide in HIV-1-Infected Pediatric Patients Over 48 Weeks of Treatment. J Clin Pharmacol 47: 510-517 [Abstract] [Full Text]  
• Staszewski, S., Babacan, E., Stephan, C., Haberl, A., Carlebach, A., Gute, P., Klauke, S., Hermschulte, Y., Stuermer, M., Dauer, B., for the Frankfurt HIV Cohort, (2006). The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J Antimicrob Chemother 58: 1024-1030 [Abstract] [Full Text]  
• Aquaro, S., D'Arrigo, R., Svicher, V., Perri, G. D., Caputo, S. L., Visco-Comandini, U., Santoro, M., Bertoli, A., Mazzotta, F., Bonora, S., Tozzi, V., Bellagamba, R., Zaccarelli, M., Narciso, P., Antinori, A., Perno, C. F. (2006). Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 58: 714-722 [Abstract] [Full Text]  
• Steger, H. K., Root, M. J. (2006). Kinetic Dependence to HIV-1 Entry Inhibition. J. Biol. Chem. 281: 25813-25821 [Abstract] [Full Text]  
• Deeks, S. G (2006). Antiretroviral treatment of HIV infected adults.. BMJ 332: 1489-1489 [Full Text]  
• Zhang, X.-Q., Sorensen, M., Fung, M., Schooley, R. T. (2006). Synergistic In Vitro Antiretroviral Activity of a Humanized Monoclonal Anti-CD4 Antibody (TNX-355) and Enfuvirtide (T-20). Antimicrob. Agents Chemother. 50: 2231-2233 [Abstract] [Full Text]  
• Westby, M., Lewis, M., Whitcomb, J., Youle, M., Pozniak, A. L., James, I. T., Jenkins, T. M., Perros, M., van der Ryst, E. (2006). Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir. J. Virol. 80: 4909-4920 [Abstract] [Full Text]  
• Briz, V., Poveda, E., Soriano, V. (2006). HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 57: 619-627 [Abstract] [Full Text]  
• Strizki, J. M., Tremblay, C., Xu, S., Wojcik, L., Wagner, N., Gonsiorek, W., Hipkin, R. W., Chou, C.-C., Pugliese-Sivo, C., Xiao, Y., Tagat, J. R., Cox, K., Priestley, T., Sorota, S., Huang, W., Hirsch, M., Reyes, G. R., Baroudy, B. M. (2005). Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 49: 4911-4919 [Abstract] [Full Text]  
• Mink, M., Mosier, S. M., Janumpalli, S., Davison, D., Jin, L., Melby, T., Sista, P., Erickson, J., Lambert, D., Stanfield-Oakley, S. A., Salgo, M., Cammack, N., Matthews, T., Greenberg, M. L. (2005). Impact of Human Immunodeficiency Virus Type 1 gp41 Amino Acid Substitutions Selected during Enfuvirtide Treatment on gp41 Binding and Antiviral Potency of Enfuvirtide In Vitro. J. Virol. 79: 12447-12454 [Abstract] [Full Text]  
• Blanco, J., Clotet-Codina, I., Bosch, B., Armand-Ugon, M., Clotet, B., Este, J. A. (2005). Multiparametric Assay To Screen and Dissect the Mode of Action of Anti-Human Immunodeficiency Virus Envelope Drugs. Antimicrob. Agents Chemother. 49: 3926-3929 [Abstract] [Full Text]  
• Takashima, K., Miyake, H., Kanzaki, N., Tagawa, Y., Wang, X., Sugihara, Y., Iizawa, Y., Baba, M. (2005). Highly Potent Inhibition of Human Immunodeficiency Virus Type 1 Replication by TAK-220, an Orally Bioavailable Small-Molecule CCR5 Antagonist. Antimicrob. Agents Chemother. 49: 3474-3482 [Abstract] [Full Text]  
• Rudorf, D. C., Krikorian, S. A. (2005). Adverse Effects Associated With Antiretroviral Therapy and Potential Management Strategies. Journal of Pharmacy Practice 18: 258-277 [Abstract]  
• Huerta, L., Gomez-Icazbalceta, G., Soto-Ramirez, L., Viveros-Rogel, M., Rodriguez, R., Fuentes, L., Lamoyi, E., Larralde, C. (2005). Human immunodeficiency virus 1 (HIV-1) envelope-dependent cell-cell fusion modulation by HIV-positive sera is related to disease progression. J. Gen. Virol. 86: 1961-1966 [Abstract] [Full Text]  
• Rusert, P., Kuster, H., Joos, B., Misselwitz, B., Gujer, C., Leemann, C., Fischer, M., Stiegler, G., Katinger, H., Olson, W. C., Weber, R., Aceto, L., Gunthard, H. F., Trkola, A. (2005). Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors. J. Virol. 79: 8454-8469 [Abstract] [Full Text]  
• Yang, Q.-e., Stephen, A. G., Adelsberger, J. W., Roberts, P. E., Zhu, W., Currens, M. J., Feng, Y., Crise, B. J., Gorelick, R. J., Rein, A. R., Fisher, R. J., Shoemaker, R. H., Sei, S. (2005). Discovery of Small-Molecule Human Immunodeficiency Virus Type 1 Entry Inhibitors That Target the gp120-Binding Domain of CD4. J. Virol. 79: 6122-6133 [Abstract] [Full Text]  
• Xu, L., Pozniak, A., Wildfire, A., Stanfield-Oakley, S. A., Mosier, S. M., Ratcliffe, D., Workman, J., Joall, A., Myers, R., Smit, E., Cane, P. A., Greenberg, M. L., Pillay, D. (2005). Emergence and Evolution of Enfuvirtide Resistance following Long-Term Therapy Involves Heptad Repeat 2 Mutations within gp41. Antimicrob. Agents Chemother. 49: 1113-1119 [Abstract] [Full Text]  
• Nameki, D., Kodama, E., Ikeuchi, M., Mabuchi, N., Otaka, A., Tamamura, H., Ohno, M., Fujii, N., Matsuoka, M. (2005). Mutations Conferring Resistance to Human Immunodeficiency Virus Type 1 Fusion Inhibitors Are Restricted by gp41 and Rev-Responsive Element Functions. J. Virol. 79: 764-770 [Abstract] [Full Text]  
• Lorber, B. (2004). Update in Infectious Diseases. ANN INTERN MED 141: 875-881 [Full Text]  
• Baldwin, C. E., Sanders, R. W., Deng, Y., Jurriaans, S., Lange, J. M., Lu, M., Berkhout, B. (2004). Emergence of a Drug-Dependent Human Immunodeficiency Virus Type 1 Variant during Therapy with the T20 Fusion Inhibitor. J. Virol. 78: 12428-12437 [Abstract] [Full Text]  
• Menzo, S., Castagna, A., Monachetti, A., Hasson, H., Danise, A., Carini, E., Bagnarelli, P., Lazzarin, A., Clementi, M. (2004). Genotype and Phenotype Patterns of Human Immunodeficiency Virus Type 1 Resistance to Enfuvirtide during Long-Term Treatment. Antimicrob. Agents Chemother. 48: 3253-3259 [Abstract] [Full Text]  
• Greenberg, M. L., Cammack, N. (2004). Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54: 333-340 [Abstract] [Full Text]  
• Budge, P. J., Graham, B. S. (2004). Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses. J Antimicrob Chemother 54: 299-302 [Abstract] [Full Text]  
• Yeni, P. G., Hammer, S. M., Hirsch, M. S., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., Richman, D. D., Schooley, R. T., Thompson, M. A., Vella, S., Volberding, P. A. (2004). Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel. JAMA 292: 251-265 [Abstract] [Full Text]  
• Ruxrungtham, K., Boyd, M., Bellibas, S. E., Zhang, X., Dorr, A., Kolis, S., Kinchelow, T., Buss, N., Patel, I. H. (2004). Lack of Interaction between Enfuvirtide and Ritonavir or Ritonavir-Boosted Saquinavir in HIV-1-Infected Patients. J Clin Pharmacol 44: 793-803 [Abstract] [Full Text]  
• Reeves, J. D., Miamidian, J. L., Biscone, M. J., Lee, F.-H., Ahmad, N., Pierson, T. C., Doms, R. W. (2004). Impact of Mutations in the Coreceptor Binding Site on Human Immunodeficiency Virus Type 1 Fusion, Infection, and Entry Inhibitor Sensitivity. J. Virol. 78: 5476-5485 [Abstract] [Full Text]  
• Rockstroh, J. K., Mauss, S. (2004). Clinical perspective of fusion inhibitors for treatment of HIV. J Antimicrob Chemother 53: 700-702 [Abstract] [Full Text]  
• Maggi, P., Ladisa, N., Cinori, E., Altobella, A., Pastore, G., Filotico, R. (2004). Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother 53: 678-681 [Abstract] [Full Text]  
• Yazdanpanah, Y. (2004). Costs associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 53: 558-561 [Abstract] [Full Text]  
• Richman, D. D. (2004). Benefits and limitations of testing for resistance to HIV drugs. J Antimicrob Chemother 53: 555-557 [Abstract] [Full Text]  
• Kuhmann, S. E., Pugach, P., Kunstman, K. J., Taylor, J., Stanfield, R. L., Snyder, A., Strizki, J. M., Riley, J., Baroudy, B. M., Wilson, I. A., Korber, B. T., Wolinsky, S. M., Moore, J. P. (2004). Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor. J. Virol. 78: 2790-2807 [Abstract] [Full Text]  
• Jacobson, J. M., Israel, R. J., Lowy, I., Ostrow, N. A., Vassilatos, L. S., Barish, M., Tran, D. N. H., Sullivan, B. M., Ketas, T. J., O'Neill, T. J., Nagashima, K. A., Huang, W., Petropoulos, C. J., Moore, J. P., Maddon, P. J., Olson, W. C. (2004). Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542. Antimicrob. Agents Chemother. 48: 423-429 [Abstract] [Full Text]  
• Boyd, M. A., Zhang, X., Dorr, A., Ruxrungtham, K., Kolis, S., Nieforth, K., Kinchelow, T., Buss, N., Patel, I. H. (2003). Lack of Enzyme-Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide. J Clin Pharmacol 43: 1382-1391 [Abstract] [Full Text]  
• Cuzin, L., Alvarez, M., Ferranti, S., Menichetti, F. (2003). Enfuvirtide for Prophylaxis against HIV Infection. NEJM 349: 2169-2170 [Full Text]  
• Veazey, R. S., Klasse, P. J., Ketas, T. J., Reeves, J. D., Piatak, M. Jr., Kunstman, K., Kuhmann, S. E., Marx, P. A., Lifson, J. D., Dufour, J., Mefford, M., Pandrea, I., Wolinsky, S. M., Doms, R. W., DeMartino, J. A., Siciliano, S. J., Lyons, K., Springer, M. S., Moore, J. P. (2003). Use of a Small Molecule CCR5 Inhibitor in Macaques to Treat Simian Immunodeficiency Virus Infection or Prevent Simian-Human Immunodeficiency Virus Infection. JEM 198: 1551-1562 [Abstract] [Full Text]  
• Tremblay, C. L., Poulin, D. L., Hicks, J. L., Selliah, S., Chamberland, A., Giguel, F., Kollmann, C. S., Chou, T. C., Dong, H., Hirsch, M. S. (2003). Favorable Interactions between Enfuvirtide and 1-{beta}-D-2,6-Diaminopurine Dioxolane In Vitro. Antimicrob. Agents Chemother. 47: 3644-3646 [Abstract] [Full Text]  
• Vermeire, K., Schols, D. (2003). Specific CD4 down-modulating compounds with potent anti-HIV activity. J. Leukoc. Biol. 74: 667-675 [Abstract] [Full Text]  
• Carr, A., Jenny-Avital, E. R., Lalezari, J. P., Lazzarin, A., Salgo, M. (2003). Enfuvirtide, an HIV-1 fusion inhibitor.. NEJM 349: 1770-1771 [Full Text]  
• Duffalo, M. L, James, C. W (2003). Enfuvirtide: A Novel Agent for the Treatment of HIV-1 Infection. The Annals of Pharmacotherapy 37: 1448-1456 [Abstract] [Full Text]  
• (2003). A New Class of Drugs for HIV Treatment. Journal Watch Dermatology 2003: 8-8 [Full Text]  
• (2003). A New Class of Drugs for HIV Treatment. JWatch General 2003: 5-5 [Full Text]  
• Kilby, J. M., Eron, J. J. (2003). Novel Therapies Based on Mechanisms of HIV-1 Cell Entry. NEJM 348: 2228-2238 [Full Text]  
• Tashima, K. T., Carpenter, C. C.J. (2003). Fusion Inhibition -- A Major but Costly Step Forward in the Treatment of HIV-1. NEJM 348: 2249-2250 [Full Text]  
• Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S.G., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J. Jr., Chung, J., DeMasi, R., Donatacci, L., Drobnes, C., Delehanty, J., Salgo, M., the TORO 1 Study Group, (2003). Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America. NEJM 348: 2175-2185 [Abstract] [Full Text]  
• Volberding, P. A., Baker, K. R., Levine, A. M. (2003). Human Immunodeficiency Virus Hematology. ASH Education Book 2003: 294-313 [Abstract] [Full Text]